Allergan Aesthetics Refreshes APP Loyalty Program for Aesthetic Practices

Allergan Aesthetics, an AbbVie company, has updated Allergan Partner Privileges (APP), its customer portfolio loyalty program, with simplified savings, greater benefits transparency, and expanded opportunities for practice growth. The company announced the changes August 11, 2026, citing customer feedback and changes in the aesthetics market as drivers behind the refresh.¹

The updated program introduces Portfolio Levels designed to reward purchasing volume across the Allergan Aesthetics portfolio, alongside benefits aimed at first-time APP members, growing practices, and long-standing customers.¹

Simplified Savings and Greater Transparency

The refresh streamlines APP Brand Tiers and introduces a simplified pricing discount structure intended to make savings easier for practices to understand and access. More Allergan Aesthetics products now contribute toward each Brand Tier, potentially allowing customers to reach additional benefits sooner.¹

Practices can also see net pricing at the time of ordering, with prices reflecting savings earned through their APP status. APP status and progress toward upgrades can be tracked in real time.

According to Allergan Aesthetics, the changes were developed in response to customer feedback identifying simplicity and transparency as priorities for practices using the program.¹

Nicole Mowad-Nassar, senior vice president at AbbVie and president of Global Allergan Aesthetics, said customers were seeking "greater simplicity, more transparency and rewards" better aligned with how their businesses operate and grow.¹

READ MORE ON PROFESSIONAL DEVELOPMENT

Portfolio Levels Reward Growth Across Product Categories

Another central change is the introduction of Portfolio Levels, which expand the program's focus beyond individual product categories.

Eligible purchases across the Allergan Aesthetics portfolio can contribute toward higher APP discounts as purchasing volume increases. The company's aesthetics portfolio spans facial injectables, body contouring, plastic surgery, skin care, and other products.¹

MORE ON AESTHETICS

The structure also introduces rewards targeted toward different stages of practice development rather than limiting additional benefits to established, high-volume customers. First-time APP members, growing practices, and long-standing customers are among the groups eligible for new reward opportunities.¹

For practices already participating in APP, the broader portfolio structure may provide additional pathways toward higher discount levels based on purchasing patterns across product categories.

Practice Growth Remains a Focus in Aesthetic Medicine

The program update comes as aesthetic practices navigate changing patient demographics and demand.

Recent Allergan Aesthetics data presented at the 2026 American Academy of Dermatology Annual Meeting found practices reported approximately 137% growth in patients receiving glucagon-like peptide-1 (GLP-1) agonists between 2023 and 2024.² Approximately 32% of these patients were reportedly new to aesthetic practices, suggesting medical weight loss may be introducing a new group of patients to aesthetic care.²

Cost, however, remains a significant consideration. In the same data set, 82% of providers identified cost as a barrier preventing GLP-1-treated patients from pursuing aesthetic treatment.²

Business development challenges extend beyond patient treatment decisions. Previous Dermatology Times coverage of Allergan Aesthetics' 2026 Confidence Collective highlighted reported gaps in financial literacy, access to capital and professional networks, and formal mentorship among women entrepreneurs.³

Together, these trends underscore the increasing intersection between clinical care and practice management as aesthetic practices respond to evolving patient populations and business demands.

New BOTOX Cosmetic Growth Benefit

Alongside the broader APP changes, Allergan Aesthetics introduced a BOTOX Cosmetic (onabotulinumtoxinA) Growth Benefit for eligible customers.

Practices achieving qualifying quarterly growth can receive a quarterly rebate on eligible BOTOX Cosmetic purchases.¹ According to the company, the benefit is intended to provide an additional incentive for practice growth beyond the standard savings available through APP.

The Growth Benefit applies to purchasing volume and does not change the approved indications or safety profile of BOTOX Cosmetic.

BOTOX Cosmetic Indications and Safety

BOTOX Cosmetic is FDA approved in adults for the temporary improvement in the appearance of moderate to severe glabellar lines, lateral canthal lines, forehead lines, and platysma bands.⁴

The prescribing information includes a boxed warning regarding distant spread of toxin effect. Postmarketing reports indicate botulinum toxin effects may spread from the injection site and produce symptoms including generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. Swallowing and breathing difficulties can be life-threatening.⁴

The prescribing information should be consulted for complete indications, contraindications, warnings, precautions, and adverse reactions.

What the APP Changes Mean for Practices

APP is designed to provide savings, rewards, and benefits across the Allergan Aesthetics portfolio.¹ The 2026 refresh shifts more emphasis toward purchasing across the broader portfolio while giving practices clearer visibility into the savings associated with their program status.

For aesthetic practices, particularly those expanding their patient base or adding services, the combination of broader Portfolio Levels, real-time status tracking, and segment-specific rewards could make it easier to determine how purchasing decisions translate into program benefits.

The separate BOTOX Cosmetic Growth Benefit adds another financial incentive for eligible practices demonstrating quarterly growth, further linking the loyalty program to practice expansion.

References

1. Allergan Aesthetics refreshes Allergan Partner Privileges® to better support today's modern aesthetics practices. News release. AbbVie. August 11, 2026. Accessed August 11, 2026. https://news.abbvie.com/2026-08-11-Allergan-Aesthetics-Refreshes-Allergan-Partner-Privileges-R-to-Better-Support-Todays-Modern-Aesthetics-Practices
2. Bosslett M. Allergan presents new phase 3 TrenibotE data and GLP-1 patient insights at AAD 2026. Dermatology Times. March 30, 2026. Accessed August 11, 2026. https://www.dermatologytimes.com/view/allergan-presents-new-phase-3-trenibote-data-and-glp-1-patient-insights-at-aad-2026
3. Bader K. Allergan Aesthetics invests in women business owners through renewed grant initiative. Dermatology Times. April 8, 2026. Accessed August 11, 2026. https://www.dermatologytimes.com/view/allergan-aesthetics-invests-in-women-business-owners-through-renewed-grant-initiative
4. BOTOX Cosmetic (onabotulinumtoxinA) prescribing information. AbbVie Inc. Accessed August 11, 2026. https://www.rxabbvie.com/pdf/botox-cosmetic_pi.pdf